ABCL
AbCellera Biologics Inc. NASDAQ Listed Dec 11, 2020$5.53
+1.65%
vs $5.44
Mkt Cap $1.7B
52w Low $2.78
74.7% of range
52w High $6.46
50d MA $4.77
200d MA $4.26
P/E (TTM)
-11.3x
EV/EBITDA
—
P/B
1.4x
Debt/Equity
0.1x
ROE
-15.1%
P/FCF
-9.5x
RSI (14)
41.60
ATR (14)
$0.52
Beta
0.85
50d MA
$4.77
200d MA
$4.26
Avg Volume
7.9M
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
2215 Yukon Street · Vancouver, BC V5Y 0A1 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | -0.18 | -0.03 | +83.3% | 3.22 | +4.3% | -0.9% | +12.5% | +0.6% | +5.8% | -2.9% | — |
| Nov 6, 2025 | AMC | -0.17 | -0.19 | -11.8% | 4.53 | -16.1% | -13.7% | +3.1% | -0.5% | -1.0% | -8.8% | — |
| Aug 7, 2025 | AMC | -0.17 | -0.12 | +29.4% | 4.24 | +13.7% | +0.2% | +5.9% | -5.1% | +7.3% | -1.7% | — |
| May 8, 2025 | AMC | -0.17 | -0.15 | +11.8% | 2.01 | +2.5% | +1.0% | +1.5% | +1.9% | -2.4% | -1.5% | — |
| Feb 27, 2025 | AMC | -0.15 | -0.11 | +26.7% | 2.92 | -6.8% | -11.3% | -8.9% | -0.8% | +2.1% | -0.4% | — |
| Nov 4, 2024 | AMC | -0.14 | -0.17 | -21.4% | 2.89 | -13.5% | -5.9% | +1.5% | -1.4% | -0.7% | +16.7% | — |
| Aug 6, 2024 | AMC | -0.15 | -0.13 | +13.3% | 2.85 | -3.5% | -7.7% | +5.3% | -3.2% | -1.5% | +1.1% | — |
| May 7, 2024 | AMC | -0.16 | -0.14 | +12.5% | 4.04 | +0.0% | -5.0% | +2.9% | -3.0% | +0.5% | -0.8% | — |
| Feb 20, 2024 | AMC | -0.14 | -0.17 | -21.4% | 5.31 | -1.1% | -9.4% | +0.8% | +0.4% | +1.6% | +3.4% | — |
| Nov 2, 2023 | AMC | -0.14 | -0.10 | +28.6% | 4.43 | -10.4% | +6.1% | -4.8% | -1.7% | -5.0% | -3.3% | — |
| Aug 3, 2023 | AMC | -0.13 | -0.11 | +15.4% | 6.97 | -6.5% | -13.3% | -3.1% | +0.7% | +2.2% | -2.3% | — |
| May 4, 2023 | AMC | -0.12 | -0.14 | -16.7% | 6.61 | -3.0% | -9.4% | -4.7% | -0.9% | +4.1% | -2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5 | Cantor Fitzgerald | Initiates | Overweight | $7 | $4.59 | $5.05 | +10.0% | +1.5% | +8.2% | -4.4% | +8.7% | +0.2% |
| Nov 7 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $4.53 | $3.80 | -16.1% | -13.7% | +3.1% | -0.5% | -1.0% | -8.8% |
| Aug 8 | Stifel | Maintains | Buy → Buy | — | $4.24 | $4.82 | +13.7% | +0.2% | +5.9% | -5.1% | +7.3% | -1.7% |
| Jul 14 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $4.01 | $4.01 | +0.0% | +5.7% | -7.1% | +3.0% | -3.9% | +14.9% |
| May 16 | Truist | Maintains | Buy → Buy | — | $2.02 | $2.03 | +0.5% | +0.5% | -0.5% | +3.5% | -4.8% | +0.5% |
| May 9 | Stifel | Maintains | Buy → Buy | — | $2.01 | $2.06 | +2.5% | +1.0% | +1.5% | +1.9% | -2.4% | -1.5% |
| Apr 16 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $2.43 | $2.45 | +0.8% | -1.6% | +1.3% | +1.2% | +2.9% | +0.4% |
| Mar 3 | Benchmark | Maintains | Hold → Hold | — | $2.59 | $2.61 | +0.8% | -8.9% | -0.8% | +2.1% | -0.4% | -2.1% |
| Feb 28 | Stifel | Maintains | Buy → Buy | — | $2.92 | $2.72 | -6.8% | -11.3% | -8.9% | -0.8% | +2.1% | -0.4% |
| Jan 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $3.28 | $3.26 | -0.6% | -7.6% | -3.6% | +2.7% | -7.7% | +6.9% |
| Nov 5 | Stifel | Maintains | Buy → Buy | — | $2.89 | $2.50 | -13.5% | -5.9% | +1.5% | -1.4% | -0.7% | +16.7% |
| Aug 20 | Benchmark | Downgrade | Buy → Hold | — | $2.71 | $2.64 | -2.6% | -4.1% | +1.5% | -4.9% | +4.0% | +3.1% |
| Jul 11 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $2.80 | $2.91 | +3.9% | +11.8% | -0.3% | +2.6% | +9.1% | -3.4% |
| May 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $4.04 | $4.04 | +0.0% | -5.0% | +2.9% | -3.0% | +0.5% | -0.8% |
| Feb 22 | Benchmark | Upgrade | Hold → Buy | — | $4.81 | $5.03 | +4.6% | +0.8% | +0.4% | +1.6% | +3.4% | -0.8% |
| Feb 21 | Stifel | Maintains | Buy → Buy | — | $5.31 | $5.25 | -1.1% | -9.4% | +0.8% | +0.4% | +1.6% | +3.4% |
| Aug 31 | Benchmark | Maintains | Buy → Buy | — | $5.80 | $5.79 | -0.2% | -6.0% | +2.6% | -0.7% | -0.7% | +0.9% |
| Aug 4 | Goldman Sachs | Maintains | Buy → Buy | — | $6.97 | $6.52 | -6.5% | -13.3% | -3.1% | +0.7% | +2.2% | -2.3% |
| May 5 | Credit Suisse | Maintains | Outperform → Outperform | — | $6.61 | $6.41 | -3.0% | -9.4% | -4.7% | -0.9% | +4.1% | -2.5% |
| Feb 28 | TD Cowen | Maintains | Outperform → Outperform | — | $8.43 | $8.49 | +0.7% | -0.4% | -3.0% | +0.4% | +2.4% | -3.3% |
| Feb 22 | Credit Suisse | Maintains | Outperform → Outperform | — | $8.89 | $8.70 | -2.1% | -1.1% | -3.2% | -1.6% | +0.7% | -0.4% |
| Feb 22 | BMO Capital | Maintains | Outperform → Outperform | — | $8.89 | $8.70 | -2.1% | -1.1% | -3.2% | -1.6% | +0.7% | -0.4% |
| Jan 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $9.65 | $9.70 | +0.5% | -1.5% | +0.4% | -1.8% | +2.3% | +6.2% |
| Dec 15 | Goldman Sachs | Maintains | Buy → Buy | — | $10.13 | $11.14 | +10.0% | +2.7% | -1.8% | -2.6% | +4.7% | +1.8% |
| Nov 16 | Truist | Maintains | Buy → Buy | — | $14.49 | $14.73 | +1.7% | +0.2% | -3.0% | +0.6% | -0.7% | -0.6% |
| Nov 9 | SVB Leerink | Maintains | Outperform → Outperform | — | $12.24 | $12.99 | +6.1% | -3.5% | +9.3% | +5.2% | +5.1% | +1.5% |
| Aug 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $11.11 | $10.72 | -3.5% | +20.1% | +0.1% | +2.4% | -1.0% | -5.8% |
| Jul 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.10 | $10.11 | +0.1% | +0.9% | +3.1% | -0.8% | -3.7% | +1.0% |
| May 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $6.64 | $6.96 | +4.8% | -13.9% | +17.3% | +7.7% | +8.0% | +4.4% |
| May 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.64 | $6.96 | +4.8% | -13.9% | +17.3% | +7.7% | +8.0% | +4.4% |
| Feb 25 | SVB Leerink | Maintains | Outperform → Outperform | — | $8.45 | $9.36 | +10.8% | +5.7% | -2.5% | +3.8% | +4.3% | -4.1% |
| Feb 25 | Credit Suisse | Maintains | Outperform → Outperform | — | $8.45 | $9.36 | +10.8% | +5.7% | -2.5% | +3.8% | +4.3% | -4.1% |
| Dec 21 | Benchmark | Maintains | Buy → Buy | — | $14.60 | $14.92 | +2.2% | +7.8% | -2.2% | -3.1% | -1.2% | -7.1% |
| Nov 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.31 | $15.57 | +1.7% | +3.2% | -8.7% | -3.2% | +3.4% | -3.1% |
| Aug 13 | Credit Suisse | Maintains | Outperform → Outperform | — | $15.19 | $15.00 | -1.3% | +17.8% | -1.3% | -6.1% | +1.0% | -5.7% |
| May 14 | Credit Suisse | Maintains | Outperform → Outperform | — | $34.14 | $31.75 | -7.0% | -7.0% | +7.6% | -3.5% | -1.9% | -1.7% |
| Mar 30 | Stifel | Maintains | Buy → Buy | — | $23.29 | $27.52 | +18.2% | +14.6% | +27.3% | -9.6% | -8.5% | +3.2% |
| Feb 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $46.55 | $49.00 | +5.3% | -3.3% | +4.4% | -0.0% | -2.1% | -6.6% |
| Jan 5 | BMO Capital | Maintains | Outperform → Outperform | — | $39.10 | $38.81 | -0.7% | -1.5% | +2.9% | -0.7% | +1.0% | -7.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | Montalbano John S.Dir | — | Buy | 20,000 | $4.77 | $95K | 241,000 | -2.64% | +1.73% |
8-K · 8.01
!! High
AbCellera Biologics Inc. -- 8-K 8.01: Material Event / Announcement
AbCellera partnered with Jazz Pharmaceuticals to develop antibody candidates for gastrointestinal cancers and solid tumors, combining AbCellera's discovery platform with Jazz's development expertise.
Jun 17
8-K
AbCellera Biologics Inc. -- 8-K Filing
Jun 12
8-K · 5.02
!!! Very High
AbCellera Biologics Inc. -- 8-K 5.02: Executive Change
Jun 5
8-K · 2.02
!! High
AbCellera Biologics Inc. -- 8-K 2.02: Earnings Results
May 11
8-K · 7.01
! Medium
AbCellera Biologics Inc. Common Shares -- 8-K 7.01: Regulation FD Disclosure
AbCellera will present 2025 financial results and corporate updates during its February 24, 2026 earnings call using a prepared presentation.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Capital World Investors | 13,361,096 | $47M | — | Mar 2026 |
| 2 | Two Sigma Investments, Lp | 10,562,065 | $37M | Added | Mar 2026 |
| 3 | Td Waterhouse Canada Inc. | 9,564,659 | $34M | Added | Mar 2026 |
| 4 | Morgan Stanley | 6,003,700 | $21M | Added | Dec 2025 |
| 5 | Ubs Group Ag | 4,209,052 | $15M | Added | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 2,999,936 | $10M | Added | Mar 2026 |
| 7 | Alyeska Investment Group, L.p. | 2,592,105 | $9M | New | Mar 2026 |
| 8 | Tudor Investment Corp | 2,273,489 | $8M | New | Mar 2026 |
| 9 | Guardian Partners Inc. | 1,786,415 | $6M | New | Mar 2026 |
| 10 | Renaissance Technologies Llc | 1,510,629 | $5M | Reduced | Mar 2026 |
| 11 | Jane Street Group, Llc | 1,397,088 | $5M | Added | Dec 2025 |
| 12 | Citadel Advisors Llc | 1,361,105 | $5M | Reduced | Mar 2026 |
| 13 | Millennium Management | 1,294,574 | $5M | Reduced | Mar 2026 |
| 14 | Hrt Financial Lp | 1,235,153 | $4M | Added | Mar 2026 |
| 15 | Point72 Asset Management | 1,149,325 | $4M | Added | Mar 2026 |
| 16 | Susquehanna International Group, Llp | 750,393 | $3M | Reduced | Mar 2026 |
| 17 | Intellectus Partners, Llc | 546,083 | $2M | Added | Mar 2026 |
| 18 | State Of Michigan Retirement System | 400,000 | $1M | — | Mar 2026 |
| 19 | Royal Bank Of Canada | 394,753 | $1M | Added | Mar 2026 |
| 20 | Marshall Wace, Llp | 359,683 | $1M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 15
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Biotechnology ETF | 1,732,022 | $6M | Mar 2026 |
| 2 | iShares Genomics Immunology and Healthcare ETF | 357,878 | $1M | Jan 2026 |
| 3 | BlackRock Advantage Small Cap Core Fund | 340,523 | $1M | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 176,961 | $639K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index ETF | 135,099 | $488K | Feb 2026 |
| 6 | Adara Smaller Companies Fund | 120,162 | $434K | Feb 2026 |
| 7 | Small Cap Value Fund | 123,712 | $432K | Mar 2026 |
| 8 | Virtus LifeSci Biotech Clinical Trials ETF | 77,824 | $282K | Jan 2026 |
| 9 | Avantis U.S. Equity ETF | 64,811 | $234K | Feb 2026 |
| 10 | Destinations Small-Mid Cap Equity Fund | 44,214 | $160K | Feb 2026 |
| 11 | Invesco RAFI Developed Markets ex-U.S. Small-Mid ETF | 40,257 | $146K | Jan 2026 |
| 12 | Avantis U.S. Small Cap Equity ETF | 39,804 | $144K | Feb 2026 |
| 13 | Invesco Nasdaq Biotechnology ETF | 16,724 | $60K | Feb 2026 |
| 14 | ProShares Ultra Nasdaq Biotechnology | 13,822 | $50K | Feb 2026 |
| 15 | Avantis U.S. Equity Fund | 9,145 | $33K | Feb 2026 |
Valuation
Market Cap
$1.65B
Enterprise Value
$1.09B
P/E (TTM)
-11.29x
Forward P/E
—
PEG Ratio
0.64x
P/B
1.45x
P/S
21.99x
P/FCF
-9.49x
EV/EBITDA
—
Shares Out
298.7M
Financials (TTM)
Revenue
$75.1M
Net Income
-$146.4M
EBITDA
-$155.4M
Free Cash Flow
-$174.1M
Op Cash Flow
-$131.3M
EPS Basic
$-0.49
EPS Diluted
$-0.49
EPS Forward
$-0.66
Gross Margin
100.0%
Op Margin
-289.0%
Net Margin
-194.9%
Balance Sheet
Total Assets
$1.36B
Total Liab.
$215.6M
Total Equity
$1.14B
Cash
$560.3M
LT Debt
$0
Book Value/Sh
$3.82
Debt/Equity
0.13x
Current Ratio
11.32
Quick Ratio
11.23
Returns & Growth
ROE
-15.1%
ROA
-10.8%
ROIC
-13.8%
Rev Growth YoY
+160.6%
EPS Growth YoY
+10.9%
Price Returns
2W
+40.2%
1M
+48.7%
3M
+70.9%
6M
+65.4%
12M
+205.4%
Technicals
52W High
$6.46
52W Low
$2.78
50d MA
$4.77
200d MA
$4.26
RSI (14)
41.60
ATR (14)
$0.52
Beta
0.85
Avg Volume
7.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$20.17
High
$34.00
Low
$5.00
Median
$23.50
Data updated apr 24, 2026 10:12am
· Source: financialmodelingprep.com